Repeated loco-regional therapies for hepatocellular carcinoma is associated with inferior outcome after living donor liver transplantation in cirrhotic patients

被引:3
作者
Tsou, Yi-Fan [1 ]
Lin, Niang-Cheng [1 ]
Hsia, Cheng-Yuan [1 ,2 ]
Loong, Che-Chuan [1 ,2 ]
Tsai, Hsin-Lin [1 ,3 ]
Chen, Cheng-Yen [1 ]
Lei, Hao-Jan [1 ,2 ]
Chou, Shu-Cheng [1 ,2 ]
Chung, Meng-Hsuan [1 ]
Kuo, Fang-Cheng [1 ]
Liu, Chin-Su [1 ,3 ]
机构
[1] Taipei Vet Gen Hosp, Dept Surg, Div Transplantat Surg, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Surg, Div Pediat Surg, Taipei, Taiwan
关键词
Hepatocellular carcinoma; Liver transplantation; Living donor liver transplantation; Loco-regional therapy; Outcomes; CHEMOEMBOLIZATION; IMPACT;
D O I
10.1097/JCMA.0000000000000670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Liver transplantation is the definitive treatment for defined stage hepatocellular carcinoma (HCC) in cirrhotic patients. Loco-regional therapy (LRT) may be considered before transplantation to prevent the disease progression and the patient from dropping out of the waiting list. This study aims to evaluate the impact of repeated pretransplant LRTs on the long-term outcomes in HCC liver transplant recipients. Methods: Between 2004 and 2019, living donor liver transplantation (LDLT) recipients with viable HCC on the explant livers were enrolled. Uni- and multivariate analysis was performed with the Cox regression model to stratify the risk factors associated with HCC recurrence and patent survival after LDLT. Results: A total of 124 patients were enrolled, in which 65.3% (n = 81) were Barcelona Clinic Liver Cancer classification stage B or D and 89% (n = 110) had advanced fibrosis or cirrhosis on the explanted livers. After a median follow-up of 41 months (IQR: 24-86.5), there were 18 cases (13.7%) of HCC recurrence. Univariate analysis showed that the model of end-stage liver disease and Child-Turcotte-Pugh score, pretransplant alpha-fetoprotein value (>500 ng/ml), repeated pretransplant LRTs (N > 4), increased tumor numbers and maximal size, presence of microvascular invasion, and the histological grading of the tumors are risk factors of inferior outcomes. In multivariate analysis, only repeated pretransplant LRTs (N > 4) had a significant impact on both the overall- and recurrence-free survival. The impact of pretransplant LRT was consistently significant among subgroups based on their LRT episodes (N = 0, 1-4, >4 respectively). Conclusion: Repeated LRT for HCC can be associated with the risk of tumor recurrence and inferior patient survival after LDLT in cirrhotic patients. Early referral of those eligible for transplantation may improve the treatment outcomes in these patients.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [41] An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma
    Bimonte, Sabrina
    Barbieri, Antonio
    Palaia, Raffaele
    Leongito, Maddalena
    Albino, Vittorio
    Piccirillo, Mauro
    Arra, Claudio
    Izzo, Francesco
    INFECTIOUS AGENTS AND CANCER, 2015, 10
  • [42] An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma
    Sabrina Bimonte
    Antonio Barbieri
    Raffaele Palaia
    Maddalena Leongito
    Vittorio Albino
    Mauro Piccirillo
    Claudio Arra
    Francesco Izzo
    Infectious Agents and Cancer, 10
  • [43] Indications for living donor liver transplantation in patients with hepatocellular carcinoma
    Sugawara, Yasuhiko
    Inomata, Yukihiro
    HEPATOBILIARY SURGERY AND NUTRITION, 2016, 5 (05) : 429 - 432
  • [44] Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria
    Cho, Yuri
    Lee, Jeong-Hoon
    Lee, Dong Hyeon
    Cho, Eun Ju
    Yu, Su Jong
    Yi, Nam-Joon
    Lee, Kwang-Woong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Suh, Kyung-Suk
    ONCOTARGET, 2017, 8 (29) : 1 - 10
  • [45] Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma
    Yoon, Young-In
    Song, Gi-Won
    Lee, Sung-Gyu
    Hwang, Shin
    Kim, Ki-Hun
    Kim, Seok-Hwan
    Kang, Woo-Hyoung
    Cho, Hwui-Dong
    Jwa, Eun-Kyoung
    Kwon, Jae-Hyun
    Tak, Eun-Young
    Kirchner, Varvara A.
    JOURNAL OF HEPATOLOGY, 2018, 68 (06) : 1153 - 1162
  • [46] Loco-regional treatments on the liver transplant waiting list: unmasking hepatocellular carcinoma (HCC) biology
    Benmassaoud, Amine
    Tsochatzis, Emmanuel A.
    HEPATOBILIARY SURGERY AND NUTRITION, 2018, 7 (03) : 199 - 201
  • [47] Impact of ABO-incompatibility on hepatocellular carcinoma recurrence after living donor liver transplantation
    Kim, Seong Hoon
    Lee, Eung Chang
    Na, Byung Gon
    Park, Sang Jae
    EJSO, 2019, 45 (02): : 180 - 186
  • [48] Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma
    Ogawa, Kohei
    Kaido, Toshimi
    Okajima, Hideaki
    Fujimoto, Yasuhiro
    Yoshizawa, Atsushi
    Yagi, Shintaro
    Hori, Tomohide
    Iida, Taku
    Takada, Yasutsugu
    Uemoto, Shinji
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2019, 26 (02) : 73 - 81
  • [49] Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria
    Ivanics, Tommy
    Claasen, Marco P. A. W.
    Samstein, Benjamin
    Emond, Jean C.
    Fox, Alyson N.
    Pomfret, Elizabeth
    Pomposelli, James
    Tabrizian, Parissa
    Florman, Sander S.
    Mehta, Neil
    Roberts, John P.
    Emamaullee, Juliet A.
    Genyk, Yuri
    Hernandez-Alejandro, Roberto
    Tomiyama, Koji
    Sasaki, Kazunari
    Hashimoto, Koji
    Nagai, Shunji
    Abouljoud, Marwan
    Olthoff, Kim M.
    Hoteit, Maarouf A.
    Heimbach, Julie
    Taner, Timucin
    Liapakis, AnnMarie H.
    Mulligan, David C.
    Sapisochin, Gonzalo
    Halazun, Karim J.
    ANNALS OF SURGERY, 2024, 279 (01) : 104 - 111
  • [50] miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver
    Chen, Hong-Yuan
    Han, Zhong-Bo
    Fan, Jun-Wei
    Xia, Jun
    Wu, Jun-Yi
    Qiu, Guo-Qiang
    Tang, Hua-Mei
    Peng, Zhi-Hai
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1859 - 1865